ENDOPROTECH, INC.

Basic Information

1044 E CHESTNUT ST
LOUISVILLE, KY, 40204-1019

Company Profile

n/a

Additional Details

Field Value
DUNS: 144667602
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease

    Amount: $664,616.00

    DESCRIPTION provided by applicant Alcoholic Liver Disease ALD remains a leading cause of death from liver disease in the U S and no FDA approved therapy exists Abnormal cytokine metabolism is ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease

    Amount: $277,707.00

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) remains a leading cause of death from liver disease in the U.S., and there is still no FDA-approved therapy. Abnormal cytokine metabo ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. New anti-complement therapy to reduce reperfusion injury: Phase II

    Amount: $963,666.00

    DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to d ...

    STTR Phase II 2008 Department of Health and Human Services
  4. New anti-complement therapy to reduce reperfusion injury

    Amount: $122,978.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia rep ...

    STTR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government